Literature DB >> 31242345

Sarcopenia in Chronic Liver Disease: Impact on Outcomes.

Poh Hwa Ooi1, Amber Hager1, Vera C Mazurak1, Khaled Dajani2, Ravi Bhargava3, Susan M Gilmour4,5, Diana R Mager1,4.   

Abstract

Malnutrition is a common complication in patients with end-stage liver disease (ESLD) awaiting liver transplantation (LT). Malnutrition and sarcopenia overlap in etiology and outcomes, with sarcopenia being defined as reduced skeletal muscle mass and muscle function. The purpose of this review was to identify the prevalence of sarcopenia with and without obesity in adults and children with ESLD and to assess the methodological considerations in sarcopenia diagnosis and the association of sarcopenia with pre- and post-LT outcomes. A total of 38 articles (35 adult and 3 pediatric articles) retrieved from PubMed or Web of Science databases were included. In adults, the prevalence rates of pre-LT sarcopenia, pre-LT sarcopenic obesity (SO), post-LT sarcopenia, and post-LT SO were 14%-78%, 2%-42%, 30%-100%, and 88%, respectively. Only 2 adult studies assessed muscle function in patients diagnosed with sarcopenia. The presence of pre-LT sarcopenia is associated with higher wait-list mortality, greater postoperative mortality, higher infection risk and postoperative complications, longer intensive care unit (ICU) stay, and ventilator dependency. The emerging pediatric data suggest that sarcopenia is prevalent in pre- and post-LT periods. In 1 pediatric study, sarcopenia was associated with poor growth, longer perioperative length of stay (total/ICU) and ventilator dependency, and increased rehospitalization in children after LT. In conclusion, there is a high prevalence of sarcopenia in adults and children with ESLD. Sarcopenia is associated with adverse clinical outcomes. The present review is limited by heterogeneity in the definition of sarcopenia and in the methodological approaches in assessing sarcopenia. Future studies are needed to standardize the sarcopenia diagnosis and muscle function assessment, particularly in the pediatric population, to enable early identification and treatment of sarcopenia in adults and children with ESLD.
Copyright © 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 31242345     DOI: 10.1002/lt.25591

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  21 in total

Review 1.  The Impact of Frailty, Sarcopenia, and Malnutrition on Liver Transplant Outcomes.

Authors:  Nikki Duong; Brett Sadowski; Amol S Rangnekar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 2.  Physical Function, Physical Activity, and Quality of Life After Liver Transplantation.

Authors:  Michael A Dunn; Shari S Rogal; Andres Duarte-Rojo; Jennifer C Lai
Journal:  Liver Transpl       Date:  2020-05       Impact factor: 5.799

3.  The Clinical Impact of Cirrhosis on the Hospital Outcomes of Patients Admitted With Influenza Infection: Propensity Score Matched Analysis of 2011-2017 US Hospital Data.

Authors:  David U Lee; Gregory H Fan; David J Hastie; Vibhav N Prakasam; Elyse A Addonizio; Ryan R Ahern; Kristen J Seog; Raffi Karagozian
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

4.  Sarcopenic Obesity in Children and Adolescents: A Systematic Review.

Authors:  Marcela Zembura; Paweł Matusik
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-01       Impact factor: 6.055

Review 5.  Sarcopenia in cirrhosis: A practical overview.

Authors:  Amritpal Dhaliwal; Matthew J Armstrong
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

6.  Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

7.  Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

8.  Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma.

Authors:  Aliya Qayyum; Priya Bhosale; Rizwan Aslam; Rony Avritscher; Jingfei Ma; Mark D Pagel; Jia Sun; Yehia Mohamed; Asif Rashid; Laura Beretta; Ahmed O Kaseb
Journal:  Abdom Radiol (NY)       Date:  2020-09-24

9.  Walking Speed: Japanese Data in Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Kazunori Yoh; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Noriko Ishii; Yukihisa Yuri; Takashi Nishimura; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Clin Med       Date:  2020-01-07       Impact factor: 4.241

Review 10.  Clinical and biomarker assessment of frailty in liver transplantation.

Authors:  Tumininu Ayorinde; Guergana Panayotova; Aanchal Sharma; Keri E Lunsford
Journal:  Curr Opin Organ Transplant       Date:  2021-10-01       Impact factor: 2.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.